The US Food and Drug Administration (FDA) has approved a labeling supplement allowing for repeat administration of iDose TR (Glaukos), an intracameral travoprost implant for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The approval permits re-treatment using a defined repeat treatment protocol and is based on accumulated clinical data supporting the safety and tolerability of repeat use.

Under the updated labeling, physicians may re-administer iDose TR in patients who maintain healthy corneal endothelial parameters. Clinical studies have shown no clinically significant corneal endothelial cell loss through 3 years of follow-up in phase 2b and phase 3 trials, the company said in a press release. Additional data from an exchange trial demonstrated that removal of the original implant followed by a second iDose TR administration was safe and well tolerated over 12 months.

iDose TR is designed to provide continuous, long-duration delivery of a proprietary formulation of travoprost directly to the anterior chamber, eliminating the need for daily topical therapy. The device is implanted through the trabecular meshwork into scleral tissue and delivers medication via membrane-controlled diffusion. iDose TR was commercially launched in the United States in 2024.